# Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

Study · id `cardio:ct-nct05238519` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05238519](<https://clinicaltrials.gov/study/NCT05238519>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05238519

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.

## Technical summary

Registry record NCT05238519. Randomized; no masking; primary purpose screening. Start 2022-02-15 (actual); primary completion 2024-11-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose screening
- Phase: Phase 3
- Enrolled: 257 participants (enrolled count; ClinicalTrials.gov record NCT05238519, source copy `cardio:ctgov-nct05238519-2026-09-04`, retrieved 2026-10-31)
- Started: 2022-02-15 (actual) (ClinicalTrials.gov record NCT05238519, source copy `cardio:ctgov-nct05238519-2026-09-04`, retrieved 2026-10-31)
- Primary completion: 2024-11-06 (actual) (ClinicalTrials.gov record NCT05238519, source copy `cardio:ctgov-nct05238519-2026-09-04`, retrieved 2026-10-31)
- Completion: 2025-08-21 (actual) (ClinicalTrials.gov record NCT05238519, source copy `cardio:ctgov-nct05238519-2026-09-04`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT05238519, source copy `cardio:ctgov-nct05238519-2026-09-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05238519-2026-09-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
- Acronym: ID-FH
- Condition: Familial Hypercholesterolemia
- Condition: Cholesterol, Elevated
- Condition: Genetic Disease
- Intervention (Behavioral): Motivational interview (MI)
- Lead sponsor: Essentia Health
- Lead sponsor class: OTHER
- Collaborator: WHITESIDE Institute for Clinical Research
- Collaborator class: UNKNOWN
- Collaborator: Aspirus St. Luke's Hospital
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)

## Provenance

Content hash: 905607ab85d592c5bad4eb7cdce2502b8ff5682f00f0a478ff19da69be62891e
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
